Search global stocks & ETFs...Ctrl K

Learn Mode

ADMA - ADMA Biologics Inc

41

$8.27

-$0.23 (-2.706%)

At market close

$8.26

-$0.009 (-0.109%)

After Hours 5/15/26, 11:23 PM

Score

4.39/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

ADMA

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$1.92B

Industry

Biotechnology

EPS (TTM)

$0.68

P/E (TTM)

11.59

Div & Yield

FCF Payout Ratio

P/S (TTM)

3.76

P/B

4.91

Diluted Shares

239.96M

Ex-Dividend

Next Earnings

08-04

Forward P/E

8.08

Payout Ratio

P/FCF (TTM)

17.82

FCF Yield

5.61%

Earnings Yield

8.63%

52 Week Range

Score Card

Explore Scores Tab

4.39

Very Good

ADMA Biologics Inc has grown revenue at 10.99% over the past year, which is strong growth. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Model

Key Score

1.00

Very Bad

Management

4.00

Good

Growth

2.00

Bad

Profitability

4.00

Good

Fin. Health

4.00

Good

Dividends

Analyst

4.00

Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

2 new filings were in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-14 07:00:16

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-12 17:22:51

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-06 17:16:25

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-06 16:10:40

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-04 07:05:47

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-29 16:28:31

Form ARS

Unknown Form Type

Filed on 2026-04-15 16:40:20

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-15 16:35:27

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-15 16:30:44

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-03 21:00:32

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-27 07:05:42

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 15:12:08

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$31.50

280.9%

Avg:

$23.12

179.6%

Low:

$17.17

107.6%

(% change is relative to the current stock price: $8.27)

Analyst Recommendations

Go to Analyst Tab

4.00

Good

20%

Strong Buy (2)

60%

Buy (6)

20%

Hold (2)

Sell (0)

Strong Sell (0)

About

Website
https://www.admabiologics.com/
Address
465 State Route 17, Ramsey NEW JERSEY, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1368514

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

IPO Date

2013-10-17

Industry

Biotechnology

Total Employees

644

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

ADMA - ADMA Biologics Inc

41

$8.27

-$0.23 (-2.706%)

$8.26

-$0.009 (-0.109%)

4.39/5

Stock Unlock

Stock Profile

Score Card

Very Good

Insider Transactions

Market News

Form 4

Filed on 2026-05-14 07:00:16

Form 4

Filed on 2026-05-12 17:22:51

Form 10-Q

Filed on 2026-05-06 17:16:25

Form 8-K

Filed on 2026-05-06 16:10:40

Form 8-K

Filed on 2026-05-04 07:05:47

Form SCHEDULE 13G

Filed on 2026-04-29 16:28:31

Form ARS

Filed on 2026-04-15 16:40:20

Form DEFA14A

Filed on 2026-04-15 16:35:27

Form DEF 14A

Filed on 2026-04-15 16:30:44

Form 4

Filed on 2026-04-03 21:00:32

Form 8-K

Filed on 2026-03-27 07:05:42

Form SCHEDULE 13G/A

Filed on 2026-03-26 15:12:08

Financials

Price Targets

280.9%

179.6%

107.6%

Analyst Recommendations

About

Similar Stocks